I think you just restated my point, while leading with a statement saying I overstated the ease?
You seem to neglect a basic fact - SR-aGVHD occurs after a stem cell transplant. An insurance company covering a transplant that could cost $500,000 won't be saying no to a treatment that treats a highly foreseeable complication.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $2.012B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.57 | $6.922M | 4.377M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 81831 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |